ATAI N Stock Overview
A clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Atai Life Sciences N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.32 |
| 52 Week High | US$37.32 |
| 52 Week Low | US$28.75 |
| Beta | 0.92 |
| 1 Month Change | 11.54% |
| 3 Month Change | 23.05% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -46.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATAI N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.3% |
| 1Y | n/a | -13.8% | 2.1% |
Return vs Industry: Insufficient data to determine how ATAI N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ATAI N performed against the MX Market.
Price Volatility
| ATAI N volatility | |
|---|---|
| ATAI N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.1% |
Stable Share Price: ATAI N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ATAI N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 83 | Florian Brand | www.atai.life |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
Atai Life Sciences N.V. Fundamentals Summary
| ATAI N fundamental statistics | |
|---|---|
| Market cap | Mex$5.47b |
| Earnings (TTM) | -Mex$677.61m |
| Revenue (TTM) | Mex$5.29m |
1,034x
P/S Ratio-8.1x
P/E RatioIs ATAI N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATAI N income statement (TTM) | |
|---|---|
| Revenue | US$314.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$314.00k |
| Other Expenses | US$40.54m |
| Earnings | -US$40.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -12,810.19% |
| Debt/Equity Ratio | 8.3% |
How did ATAI N perform over the long term?
See historical performance and comparison